09/763,740 => d his (FILE 'HOME' ENTERED AT 12:46:36 ON 01 MAY 2002) FILE 'REGISTRY' ENTERED AT 12:47:08 ON 01 MAY 2002 STRUCTURE UPLOADED L11 S L1 L2L3 22 S L1 FUL FILE 'REGISTRY' ENTERED AT 12:48:04 ON 01 MAY 2002 **L4** FILE 'CAPLUS' ENTERED AT 12:48:15 ON 01 MAY 2002 1 S L3 L5 => d l1 L1 HAS NO ANSWERS STR L1*** STRUCTURE DIAGRAM IS NOT AVAILABLE *** Structure attributes must be viewed using STN Express query preparation. => d bib abs hitstr 15 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS L_5 1998:65889 CAPLUS ΑN DN 128:127826 Preparation of new amidino derivatives as thrombin inhibitors ΤТ Antonsson, Thomas IN Astra Aktiebolag, Swed.; Antonsson, Thomas PA SO PCT Int. Appl., 108 pp. CODEN: PIXXD2 DTPatent LAEnglish FAN.CNT 1 KIND DATE APPLICATION NO. DATE PATENT NO. ----______ 19970626 19980115 WO 1997-SE1150 WO 9801422 PΙ A1 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG CA 1997-2260190 19970626 AA 19980115 CA 2260190 AU 1997-35628 19970626 19980202 AU 9735628 Α1 AU 726236 B2 20001102 EP 1997-932085 19970626 19990526 EP 917528 A1 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO BR 1997-10142 19970626 19990810 BR 9710142 Α 19990915 CN 1997-197578 19970626 Α CN 1228765 JP 2000515505 20001121 JP 1998-505123 19970626 T2 US 1997-894833 19970829

В1

Α

Α

Α

US 6221898

NO 9806180

KR 2000022437

US 2002040043 PRAI SE 1996-2646

20010424

19990304

20000425

19960704

A1 20020404

19981229

19981230

20010423

NO 1998-6180

KR 1998-710870

US 2001-839609

WO 1997-SE1150 W 19970626 US 1997-894833 A3 19970829 OS MARPAT 128:127826 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

The title compds. [I; one of R1 and R2 = Z-SO2-Ar1 and the other = R4; Z = O, NR5; R3 = Oh, halo, Cn, etc.; R4 = H, OH, halo, etc.; Ar1 = Ph, C1-3 alkylphenyl, naphthyl, etc.; R5 = H, C1-6 alkyl, Ph, C1-3 alkylphenyl; Y = O, S, S(O), SS(O)2, NR22; R22 = H, C1-4 alkyl; n = 0-4; B = II, III, IV, V; X1, X2 = a single bond, CH2], useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants, were prepd. Thus, reaction of 3-[2-(4-cyanophenyl)ethoxy]aniline with benzenesulfonyl chloride followed by treatment of the resulting N-{3-[2-(4-cyanophenyl)ethoxy]phenyl}benzene sulfonamide with HCl(g) in EtOH, and treating N-{3-[2-(4-ethoxyiminomethylphenyl)ethoxy]phenyl}benzenesulfonamide.HCl with NH3(g) afforded the title compd. VI. The title compds. I described herein were tested for thrombin inhibition and were found to exhibit an IC50 and/or Ki (as appropriate) of < 0.3 .mu.M.

IT 201933-65-5P 201933-67-7P 201933-68-8P 201933-69-9P 201933-70-2P 201933-71-3P 201933-72-4P 201933-73-5P 201933-80-4P 201933-81-5P 201933-82-6P 201933-83-7P 201933-84-8P 201933-85-9P 201934-61-4P 201934-62-5P 201934-63-6P 201934-64-7P 201934-65-8P 201934-71-6P 201934-72-7P 201935-44-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of new amidino derivs. as thrombin inhibitors)

RN 201933-65-5 CAPLUS

CN

Benzenecarboximidamide, 4-[2-[3-[(phenylsulfonyl)amino]phenoxy]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

HCl

RN 201933-67-7 CAPLUS
CN Benzenecarboximidamide, 4-[2-[3-[[(2-chlorophenyl)sulfonyl]amino]phenoxy]e
thyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{NH} \\ \text{H}_2\text{N-C} \\ \\ \text{CH}_2\text{-CH}_2\text{-O} \\ \\ \text{NH-S} \\ \\ \text{O} \\ \end{array}$$

201933-68-8 CAPLUS RNBenzenecarboximidamide, 4-[2-[3-[[(2-chlorophenyl)sulfonyl]amino]phenoxy]e CN

thyl]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 201933-67-7

CMF C21 H20 C1 N3 O3 S

$$\begin{array}{c} \text{NH} \\ \text{H}_2\text{N-C} \\ \\ \text{CH}_2\text{-CH}_2\text{-O} \\ \\ \text{NH-S} \\ \\ \text{O} \\ \end{array}$$

CM2

CRN 64-19-7 CMF C2 H4 O2

201933-69-9 CAPLUS RN

Benzenecarboximidamide, 4-[2-[3-[[(2-cyanophenyl)sulfonyl]amino]phenoxy]et CN hyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} \\ & \\ \text{H}_2\text{N}-\text{C} \\ & \\ \text{CH}_2-\text{CH}_2-\text{O} \\ & \\ \text{NH}-\text{S} \\ & \\ \text{O} \\ \end{array}$$

● HCl

201933-70-2 CAPLUS RN

Benzenecarboximidamide, 4-[2-[3-[[(2-fluorophenyl)sulfonyl]amino]phenoxy]e CNthyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} \\ \text{H}_2\text{N-C} \\ & \text{CH}_2\text{-CH}_2\text{-O} \\ & \text{NH-S} \\ & \text{O} \\ \end{array}$$

● HCl

201933-71-3 CAPLUS RN

Benzenecarboximidamide, 4-[2-[3-[[[2-(trifluoromethoxy)phenyl]sulfonyl]ami CNno]phenoxy]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

201933-72-4 CAPLUS RN

Benzenecarboximidamide, 4-[2-[3-[[(4-fluorophenyl)sulfonyl]amino]phenoxy]e CNthyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{NH} \\ \parallel \\ \text{H}_2\text{N-C} \\ \text{CH}_2\text{-CH}_2\text{-O} \\ \text{NH-S} \\ \text{O} \\ \end{array}$$

● HCl

201933-73-5 CAPLUS RN

Benzenecarboximidamide, 4-[2-[3-[[(2,5-dimethylphenyl)sulfonyl]amino]pheno xy]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME) CN

:

$$\begin{array}{c|c} & \text{NH} & \text{Me} \\ \\ \text{H}_2\text{N}-\text{C} & \text{O} & \text{NH}-\text{S} \\ \\ & \text{O} & \text{Me} \\ \end{array}$$

● HCl

RN 201933-80-4 CAPLUS
CN Benzenecarboximidamide, 4-[2-[3-[[(2-chlorophenyl)sulfonyl]amino]-5-methylphenoxy]ethyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} \\ & \\ \text{H}_2\text{N-C} \\ & \\ \text{CH}_2\text{-CH}_2\text{-O} \\ & \\ \text{Me} \\ \end{array}$$

RN 201933-81-5 CAPLUS
CN Benzenecarboximidamide, 4-[2-[3-[[(2-chlorophenyl)sulfonyl]amino]-5-methylphenoxy]ethyl]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 201933-80-4 CMF C22 H22 Cl N3 O3 S

$$\begin{array}{c} \text{NH} \\ \text{H}_2\text{N-C} \\ \text{CH}_2\text{-CH}_2\text{-O-NH-S} \\ \text{Me} \end{array}$$

CM 2

CRN 64-19-7 CMF C2 H4 O2

RN 201933-82-6 CAPLUS

CN Benzenecarboximidamide, 4-[2-[2-methyl-3-[(phenylsulfonyl)amino]phenoxy]et hyl]- (9CI) (CA INDEX NAME)

RN 201933-83-7 CAPLUS

CN Benzenecarboximidamide, 4-[2-[2-methyl-3-[(phenylsulfonyl)amino]phenoxy]et hyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 201933-82-6 CMF C22 H23 N3 O3 S

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 201933-84-8 CAPLUS

CN Benzenecarboximidamide, 4-[2-[4-methyl-3-[(phenylsulfonyl)amino]phenoxy]et hyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 201933-85-9 CAPLUS

CN Benzenecarboximidamide, 4-[2-[3-methyl-5-[(phenylsulfonyl)amino]phenoxy]et hyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{Me} & & & \\ & \text{O} & \text{CH}_2\text{--}\text{CH}_2 \\ \hline \\ \text{Ph}-\text{S} & \text{NH} & & \\ & \text{NH} \\ \end{array}$$

● HCl

RN 201934-61-4 CAPLUS

CN Benzenecarboximidamide, 4-[2-[3-[[(2-cyanophenyl)sulfonyl]amino]phenoxy]et hyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} \\ & \\ \text{H}_2\text{N-C} \\ & \\ \text{CH}_2\text{-CH}_2\text{-O} \\ & \\ \text{NH-S} \\ & \\ \text{O} \\ \end{array}$$

RN 201934-62-5 CAPLUS

CN Benzenecarboximidamide, 4-[2-[3-[[(2-fluorophenyl)sulfonyl]amino]phenoxy]e thyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{NH} \\ \parallel \\ \text{H}_2\text{N-C} \\ \\ \text{CH}_2\text{-CH}_2\text{-O} \\ \\ \text{NH-S} \\ \\ \text{O} \\ \end{array}$$

RN 201934-63-6 CAPLUS

Benzenecarboximidamide, 4-[2-[3-[[[2-(trifluoromethoxy)phenyl]sulfonyl]ami CNno]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

201934-64-7 CAPLUS RN

Benzenecarboximidamide, 4-[2-[3-[[(4-fluorophenyl)sulfonyl]amino]phenoxy]e CNthyl] - (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{NH} \\ \parallel \\ \text{H}_2\text{N-C} \\ \text{CH}_2\text{-CH}_2\text{-O} \\ \text{NH-S} \\ \text{O} \\ \end{array}$$

201934-65-8 CAPLUS RN

Benzenecarboximidamide, 4-[2-[3-[[(2,5-dimethylphenyl)sulfonyl]amino]pheno CN xy]ethyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & & \text{Me} \\ & & \\ \text{H}_2\text{N}-\text{C} & & \\ & & \\ & & \\ \text{CH}_2-\text{CH}_2-\text{O} & & \\ & & \\ & & \\ & & \\ \text{Me} & & \\ \end{array}$$

RN201934-71-6 CAPLUS

Benzenecarboximidamide, 4-[2-[4-methyl-3-[(phenylsulfonyl)amino]phenoxy]et CN hyl] - (9CI) (CA INDEX NAME)

201934-72-7 CAPLUS RN

Benzenecarboximidamide, 4-[2-[3-methyl-5-[(phenylsulfonyl)amino]phenoxy]et CN hyl]- (9CI) (CA INDEX NAME)

RN 201935-44-6 CAPLUS CN Benzenecarboximidamide, 4-[2-[3-[(phenylsulfonyl)amino]phenoxy]ethyl]-(9CI) (CA INDEX NAME)

=>

```
C:\STNEXP4\QUERIES\839.Str
```

```
chain nodes :
. 7 8 9 10 11 12 19 20 21 26
ring nodes:
1 2 3 4 5 6 13 14 15 16 17 18
chain bonds:
5-7 7-8 8-9 8-26 9-10 10-11 11-12 12-13 19-20 19-21
ring bonds :
    1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18
exact/norm bonds :
    7-8 19-20 19-21
exact bonds: 5-7 8-9 8-26 9-10 10-11 11-12 12-13
normalized bonds:
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18
Match level:
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:CLASS 11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS 21:CLASS 22:CLASS 26:CLASS
Generic attributes :
    9:
     Saturation
                               : Unsaturated
     Number of Carbon Atoms: less than 7
     Type of Ring System : Monocyclic
Element Count:
     Node 9: Limited
         c,c6
```